X0202 SCHEDULE 13G/A 0001858703 XXXXXXXX LIVE 3 Common Stock, par value $0.001 per share 03/31/2026 0001374690 Larimar Therapeutics, Inc. 517125100 Three Bala Plaza East. Suite 506 Bala Cynwyd PA 19004 Rule 13d-1(b) Blue Owl Capital Holdings LP DE 10739492 0.00 10739492 0.00 10739492 9.99 PN The reported securities represent: (i) 7,120,007 shares of Common Stock; (ii) 975,700 shares of Common Stock issuable upon exercise of 9,757 call options; and (iii) 2,643,785 shares of Common Stock issuable upon conversion of Series A convertible preferred stock ("Series A Preferred Stock"). The reported percentage is calculated based on 103,882,937 shares of Common Stock outstanding as of March 17, 2026, as reported on the Issuer's 10-K filed with the Securities and Exchange Commission on March 19, 2026, as increased by (i) 975,700 shares of Common Stock issuable upon exercise of 9,757 call options and (ii) 2,643,785 shares of Common Stock issuable upon conversion of Series A Preferred Stock. Larimar Therapeutics, Inc. Three Bala Plaza East, Suite 506, Bala Cynwyd, PA 19004 This statement is filed by Blue Owl Capital Holdings LP, referred to herein as the "Reporting Person." 399 Park Avenue, New York, New York 10022 See response to row 4 on the cover page. N IA See response to row 9 on the cover page. The reported securities include: (i) 7,120,007 shares of Common Stock; (ii) 975,700 shares of Common Stock issuable upon exercise of 9,757 call options; and (iii) 2,643,785 shares of Common Stock issuable upon conversion of 500,000 shares of Series A Preferred Stock (which would be convertible into 5,000,000 shares of Common Stock in the absence of a conversion blocker that limits the Reporting Person's beneficial ownership to 9.99%). Pursuant to Rule 13d-4 of the Act, the Reporting Person declares that filing this statement shall not be deemed an admission that the Reporting Person is a beneficial owner of the reported securities, for purposes of Section 13(d) and/or Section 13(g) or for any other purpose. See response to row 11 on the cover page. See response to row 5 on the cover page. See response to row 6 on the cover page. See response to row 7 on the cover page. See response to row 8 on the cover page. Y Y Y Y Y N By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11. Blue Owl Capital Holdings LP /s/ Karen Hager 05/13/2026